Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope against Drug-Resistant yeast infections?

NCT ID NCT03604705

Disease control Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested an experimental drug called APX001 in 21 adults with Candida bloodstream infections, including cases where standard antifungals might not work. Participants received the drug for up to 14 days, with possible follow-up treatment. The goal was to see if the drug could clear the infection and improve survival. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
APX001 (an experimental antifungal drug)
What this could lead to
If successful, this could point toward a new treatment option for serious Candida bloodstream infections, especially those resistant to current antifungals.
What could go wrong
This is a very small, early-phase trial with only 21 participants and no comparison group. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

21 people

The number who actually took part.

Started

Oct 2018

Finished

Jul 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Provision of written consent * Adults ages 18 and above male or female * New diagnosis of candidemia * Able to have pre-existing intravascular catheters removed and replaced (as necessary) Key Exclusion Criteria: * neutropenia * deep-seated Candida-related infections * hepatosplenic candidiasis * received more than 2 days of prior systemic antifungal treatment for current candidemia episode * severe hepatic impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Candidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Candidemia

Contacts and locations

Locations

  • Augusta University (Georgia Regents University)

    Augusta, Georgia, 30901, United States

  • CHU de Charleroi - Hopital Civil Marie Curie

    Lodelinsart, Belgium

  • Duke University Hospital Medical Center

    Durham, North Carolina, 27710, United States

  • Hopital Erasme

    Brussels, 1070, Belgium

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Mutua de Terrassa

    Terrassa, Barcelona, Spain

  • Hospital VLL D Hebron

    Barcelona, Spain

  • Infectious Diseases Unit

    Tel Aviv, 6423906, Israel

  • Infectious Diseases Unit, Rambam Medical Center

    Haifa, 3109601, Israel

  • Infectious Diseases Unit,Sheba Medical Center

    Tel Litwinsky, 52621, Israel

  • Institut Jules Bordet

    Brussels, Belgium

  • Institut Jules Bordet,Service De Microbiologie

    Brussels, 1000, Belgium

  • Klinik I fur Innere Medizin- Uniklinik Koln

    Cologne, Germany

  • Mont-Godinne University Hospital

    Yvoir, 5530, Belgium

  • Rambam Medical Center

    Haifa, Israel

  • Sheba Medical Center

    Tel Litwinsky, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie

    Mainz, Germany

  • Universite Libre de Bruxelles (ULB) - Hopital Erasme

    Brussels, Belgium

  • University Hospital Heidelberg

    Heidelberg, Germany

  • University Hospital Mont-Godinne

    Yvoir, Belgium

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama, 35249, United States

  • University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama, 35233, United States

  • University of California, Davis

    Davis, California, 95616, United States

  • University of California-Davis Medical Center

    Sacramento, California, 95817, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Texas- Health Science Center and Medical School at Houston

    Houston, Texas, 77030, United States

  • Washington University

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.